

Andrea Becciolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2898740/publications.pdf>

Version: 2024-02-01

59
papers

1,157
citations

471509

17
h-index

414414

32
g-index

61
all docs

61
docs citations

61
times ranked

1989
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex and Management of Rheumatoid Arthritis. Clinical Reviews in Allergy and Immunology, 2019, 56, 333-345.	6.5	126
2	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Design, Development and Therapy, 2019, Volume 13, 57-70.	4.3	99
3	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Design, Development and Therapy, 2017, Volume 11, 1593-1603.	4.3	85
4	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. Arthritis Care and Research, 2016, 68, 432-439.	3.4	69
5	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmunity Reviews, 2017, 16, 1185-1195.	5.8	67
6	The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting. Journal of Rheumatology, 2017, 44, 279-285.	2.0	66
7	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Seminars in Arthritis and Rheumatism, 2017, 47, 183-192.	3.4	63
8	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs in Context, 2019, 8, 1-12.	2.2	55
9	Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study. Rheumatology, 2015, 54, 1826-1832.	1.9	50
10	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2016, 45, 519-532.	3.4	45
11	Bone erosions in rheumatoid arthritis: ultrasound findings in the early stage of the disease. Rheumatology, 2014, 53, 1100-1107.	1.9	44
12	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs, 2019, 79, 1741-1755.	10.9	39
13	Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs, 2019, 28, 573-581.	4.1	33
14	Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. Arthritis Care and Research, 2017, 69, 867-874.	3.4	32
15	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clinical Rheumatology, 2017, 36, 1747-1755.	2.2	31
16	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the <scp>LORHEN</scp> registry. International Journal of Rheumatic Diseases, 2018, 21, 422-430.	1.9	22
17	Interreader Reliability in Assessment of Nailfold Capillary Abnormalities by Beginners: Pilot Study of an Intensive Videocapillaroscopy Training Program. Journal of Rheumatology, 2012, 39, 1248-1255.	2.0	18
18	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Design, Development and Therapy, 2017, Volume 11, 211-223.	4.3	17

#	ARTICLE	IF	CITATIONS
19	SAT0414â€¦CLINICAL PRESENTATION OF PAGET DISEASE OF BONE: IS IT CHANGING? A RETROSPECTIVE ANALYSIS ON 368 PATIENTS. , 2019, , .		17
20	Sonographic subclinical enthesal involvement in dialysis patients. Clinical Rheumatology, 2011, 30, 907-913.	2.2	14
21	Sarilumab: patient-reported outcomes in rheumatoid arthritis. Patient Related Outcome Measures, 2018, Volume 9, 275-284.	1.2	14
22	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. Drug Design, Development and Therapy, 2018, Volume 12, 1421-1429.	4.3	13
23	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. Journal of International Medical Research, 2016, 44, 113-118.	1.0	12
24	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. BioMed Research International, 2018, 2018, 1-11.	1.9	12
25	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. Annals of the Rheumatic Diseases, 2015, 74, e5-e5.	0.9	11
26	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Drug Design, Development and Therapy, 2017, Volume 11, 1969-1978.	4.3	11
27	Structural integrity versus radiographic progression in rheumatoid arthritis: FigureÂ1. RMD Open, 2015, 1, e000064.	3.8	10
28	Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. Rheumatology International, 2020, 40, 263-272.	3.0	10
29	Mild cognitive impairment in psoriatic arthritis. Medicine (United States), 2021, 100, e24833.	1.0	9
30	Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study. Journal of Clinical Medicine, 2022, 11, 621.	2.4	9
31	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Modern Rheumatology, 2018, 28, 542-549.	1.8	8
32	Vitamin D and Spondyloarthritis: Review of the Literature. Open Rheumatology Journal, 2018, 12, 214-225.	0.2	5
33	THU0432â€¦Bone erosions in rheumatoid arthritis: Ultrasound findings in the early stage of the disease. Annals of the Rheumatic Diseases, 2013, 71, 301.2-301.	0.9	4
34	Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting. Journal of Rheumatology, 2017, 44, 262-263.	2.0	4
35	Pisotriquetral arthritis: â€˜forgottenâ€™ joint in ultrasound imaging of the wrist. Annals of the Rheumatic Diseases, 2022, 81, e97-e97.	0.9	4
36	Cycling or swap biologics and small molecules in psoriatic arthritis. Medicine (United States), 2021, 100, e25300.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Apremilast retention rate in clinical practice: observations from an Italian multi-center study. <i>Clinical Rheumatology</i> , 2022, 41, 3219-3225.	2.2	3
38	The Introduction of Etanercept Biosimilar In The Practice of A Tertiary Rheumatologic Centre In Italy: A Budget Impact Model. <i>Value in Health</i> , 2016, 19, A534.	0.3	2
39	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018, 17, 1251-1258.	5.8	2
40	Imaging in the Assessment of Musculoskeletal Manifestations Associated with Inflammatory Bowel Disease. <i>Gastroenterology Insights</i> , 2021, 12, 100-110.	1.2	2
41	bDMARDs retention rate in the biosimilar era: A real-life monocentric study. <i>European Journal of Rheumatology</i> , 2021, 8, 109-110.	0.6	2
42	Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 335.	2.5	2
43	SAT0214â€¦Reliability and Validity of the Italian Version of the UCLA-Scleroderma Clinical Trial Consortium-Gastrointestinal Tract Instrument in Patients with Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A653.1-A653.	0.9	1
44	Clinical and serological features of juvenile systemic lupus erythematosus in an Italian tertiary centre of pediatric rheumatology. <i>Pediatric Rheumatology</i> , 2014, 12, .	2.1	1
45	Sonographic findings in a case of cactus thorn arthritis. <i>Journal of Clinical Ultrasound</i> , 2017, 45, 240-241.	0.8	1
46	SAT0375â€¦MILD COGNITIVE IMPAIRMENT IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS. , 2019, , .		1
47	Comment on: Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. <i>Rheumatology</i> , 2020, 59, 1455-1456.	1.9	1
48	Internal medicine inpatientsâ€™ prevalence of misdiagnosed severe osteoporosis. <i>Osteoporosis International</i> , 2021, 32, 2361-2364.	3.1	1
49	Filgotinib as rheumatoid arthritis therapy. <i>Drugs of Today</i> , 2021, 57, 543.	1.1	1
50	SAT0413â€¦Inter-reader reliability in the assessment of nailfold capillary abnormalities: A pilot study about an intensive videocapillaroscopy training programme. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 611.3-612.	0.9	0
51	SAT0524â€¦Predictors of A Clinical Response to Bisphosphonates Treatment in Patients with Complex Regional Pain Syndrome Type I. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 781.1-781.	0.9	0
52	THU0171â€¦Which Adverse Events (AEs) of Biological Therapy (BT) Led to Discontinuation of Treatment in A Cohort of 377 JIA Patients in Comparison to 1115 Patients Affected by RA, AS, PSA in the Department of Rheumatology of G. Pini Institute. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 239.3-240.	0.9	0
53	FRI0497â€¦Drug Retention and Pattern of Discontinuation of the First-Line Anti-TNF Drug in a Large Cohort of Patients with Adult or Juvenile-Onset Inflammatory Arthritides. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 608.2-609.	0.9	0
54	FRI0111â€¦Change Over Time in the Pattern of Clinical Response to First-Line Biologic Drugs: Observational Data from a Local Registry. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 460.1-460.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Comment on: Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study: reply. Rheumatology, 2015, 54, 2117-2118.	1.9	0
56	THU0365â€¦Do extra-articular manifestations affect the choice of biologic therapy in patients with axial spondyloarthritis? a multicentre real-life analysis. , 2017, , .		0
57	FRI0042â€¦CERTOLIZUMAB PEGOL EFFECTIVENESS IN WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL MULTICENTRE COHORT. , 2019, , .		0
58	A Parsonage-Turner Syndrome secondary to Parvovirus B19 infection. Acta Biomedica, 2021, 92, e2021129.	0.3	0
59	Home-based unsupervised pulmonary rehabilitation program improves the respiratory disability in systemic sclerosis patients with dyspnea: an observational prospective study. Monaldi Archives for Chest Disease, 2021, , .	0.6	0